TrialAnnals of the rheumatic diseases2023

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).

Peter C Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.